Crinetics Pharmaceuticals, Inc.
Every calculator, already run for CRNX
Open the full toolkit →You have the numbers on CRNX. Get the argument.
A written report on which of these readings actually decide the outcome for Crinetics Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering CRNXOwnership & short interest
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess AC…
CRNX — frequently asked
Is CRNX a buy right now?
Wall Street's consensus rating on Crinetics Pharmaceuticals, Inc. is Hold across 14 analysts, with a mean price target of $85.50 (+2% vs. the current $84.00). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Crinetics Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Crinetics Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRNX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Crinetics Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.